Compounds & interventions

Antidepressants

Mind & Brain · covered by 21 outlets this week · tracked since 2026-10-27

Press: 22 mainstream 27 specialist 18 independent outlet-days

What it is

Evidence 9/10 · thoroughly established Uneven · 5–9 by use Signals · regulator warning

Antidepressants are medicines for depression and anxiety, the most widely used being SSRIs such as sertraline and fluoxetine. Trials show they help more than placebo on average, with larger effects in more severe depression, and many people take them for years. Coverage centres on which drugs work best over the long term, withdrawal symptoms when stopping, rising use in young people, and how they compare with talking therapies.

Approved and guideline-recommended for moderate to severe depression and anxiety disorders; benefit over placebo is smaller in mild depression.

Evidence by use or claim · 1 preclinical to 10 thoroughly established

  1. Moderate to severe depression9/10 · thoroughly established

    many RCTs and meta-analyses

  2. Anxiety disorders8/10 · established for some uses

    RCTs and guidelines

  3. Mild depression5/10 · mixed or limited trials

    small benefit over placebo

  • RegulatorAntidepressants carry a US FDA boxed warning about suicidal thoughts and behaviour in children and young adults.
  • RegulatorUK and US regulators have updated labels to describe withdrawal symptoms on stopping.
  • TrialTrials report sexual side effects, nausea and sleep changes as common adverse effects.

This week · A network meta-analysis of long-term treatment reported that antidepressants differ in how well they keep depression from returning, drawing wide coverage and expert reaction.

Written by the Alivewire editors from the coverage below, 16h ago; rated 16h ago. Not medical advice; how the ratings work.

Coverage